Etelcalcetide Injection (Parsabiv™)

Parsabiv (etelcalcetide) is covered for treatment of secondary hyperparathyroidism in adults (≥18) with CKD who are on hemodialysis but is excluded for patients <18, not on hemodialysis, with signs/symptoms of hypocalcemia, corrected serum calcium <7.5 mg/dL, or if used concurrently or within 7 days after cinacalcet. Coverage requires documentation of diagnosis and hemodialysis, corrected Ca ≥7.5 mg/dL, initial PTH ≥300 pg/mL (reauthorization ≥100 pg/mL), medication history, and a treatment plan for IV bolus dosing ≤15 mg up to three times weekly at the end of dialysis, with approval up to 12 months.

"Has no signs or symptoms of hypocalcemia (e."

Sign up to see full coverage criteria, indications, and limitations.